Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate

Lien vers Pubmed [PMID] – 21600602

J. Urol. 2011 Jul;186(1):302-9

Vascular targeted photodynamic therapy with WST09 shows promise for recurrent prostate cancer after radiation but hydrophobicity in aqueous solutions limited application. We tested the safety and efficacy of WST11, a novel water soluble vascular occluding agent, for vascular targeted photodynamic therapy of the dog prostate and compared it to WST09 vascular targeted photodynamic therapy.